Industry
From U.S. (Toll Free) : +16467917070    |   UK : +442030260021     |    sales@businessmarketinsights.com

Asia Pacific Hemodialysis and Peritoneal Dialysis Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Type (Hemodialysis and Peritoneal Dialysis), Product (Devices, Consumables, and Services), and End User (Hospital-Based and Home-Based)         

Report Code :  BMIRE00025821
No. of Pages :  73.
Published Month :  Sep 2022
Category :  Life Sciences
$299 per month

Best Plan
  • All Reports in One Industry
  • All Reports Read Access
  • Subscription Duration : 12 Months
  • Monthly New Reports Added
  • $1200 Yearly Saving

The hemodialysis and peritoneal dialysis market in Asia Pacific is expected to grow from US$ 19,255.20 million in 2022 to US$ 29,972.11 million by 2028; it is estimated to grow at a CAGR of 7.7% from 2022 to 2028.     

 

The increasing preference for home care dialysis is the major factor driving the Asia Pacific hemodialysis and peritoneal dialysis market. Home hemodialysis (HHD) is a kidney replacement modality for patients with end-stage kidney disease (ESKD) that can be performed safely in the patient’s home environment. It requires the assistance of a trained caregiver or qualified hemodialysis nurse. The frequency of treatment for HHD can vary as per the patient. HHD can be performed as conventional HHD, with treatments 3 days a week for 3 to 4 hours or longer each time. It can also be performed as a short daily HHD, occurring 5 to 7 times a week for a shorter duration. Lastly, it can be performed overnight as nocturnal HHD, where treatments normally last 6 to 8 hours. New, easy-to-use machines are being developed for home hemodialysis. These are easier to set up, clean, and disinfect. Although the increasing reimbursement of home dialysis would seem to be an appropriate strategy to stimulate uptake of these modalities, evidence from regions that offer high reimbursement rates for peritoneal dialysis (PD) suggests that the success of this strategy is variable.  

 

With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the Asia Pacific hemodialysis and peritoneal dialysis market. The Asia Pacific hemodialysis and peritoneal dialysis market is expected to grow at a good CAGR during the forecast period.

 

 Asia Pacific Hemodialysis and Peritoneal Dialysis Market Revenue and Forecast to 2028 (US$ Million)

 

Asia Pacific Hemodialysis and Peritoneal Dialysis Market Segmentation

 

The Asia Pacific hemodialysis and peritoneal dialysis market is segmented into type, product, end user, and country. Based on type, the market is bifurcated into hemodialysis and peritoneal dialysis. In 2022, the hemodialysis segment is expected to hold a larger market share. Based on product, the hemodialysis and peritoneal dialysis market is segmented into devices, consumables, and services. The services segment is likely to hold the largest market share in 2022. Based on end user, the market is segmented into hospital-based and home-based. The hospital-based segment is expected to account for a larger share in 2022. Based on country, the Asia Pacific hemodialysis and peritoneal dialysis market is segmented into Australia, China, India, Japan, South Korea, and the Rest of Asia Pacific. China is anticipated to hold the largest market share in 2022. 

 

Asahi Kasei Medical Co., Ltd.; B. Braun Melsungen AG; Baxter International Inc.; DaVita Inc.; Dialife SA; Diaverum; Fresenius Medical Care AG & Co KGaA; Nipro Medical Corporation; and Rockwell Medical, Inc. are among the leading companies operating in the Asia Pacific hemodialysis and peritoneal dialysis market.


 ]Checklist for all documents:

 

1.  Check whether the title is in standard format.

2.  Base year and forecast period should be consistent across all documents

3.  No discrepancy in market name and segmentation should be found.

4.  Content related to COVID impact is a must in relevant documents.

 [SM2]We must talk specifically about the companies operating in the market being considered. In case, any of the companies mentioned in the document is not relevant to the market, it should be deleted. Pls check for relevance. Ensure correctness of the names as per their copyright names given on respective websites, especially wrt spellings, punctuations, prefixes, and suffixes.

  1. Asahi Kasei Medical Co., Ltd.
  2. B. Braun Melsungen AG
  3. Baxter International Inc.
  4. DaVita Inc.
  5. Dialife SA
  6. Diaverum
  7. Fresenius Medical Care AG & Co KGaA
  8. Nipro Medical Corporation
  9. Rockwell Medical, Inc
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Asia Pacific hemodialysis and peritoneal dialysis market
  • Highlights key business priorities in order to assist companies to realign their business strategies
  • The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific hemodialysis and peritoneal dialysis market, thereby allowing players across the value chain to develop effective long-term strategies
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
  • Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the hemodialysis and peritoneal dialysis market, as well as those hindering it
  • Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing and distribution